Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy

Cancer Journal

Volumn 9, Issue 1, 2003, Pages 33-41

  Buchholz, Thomas A ^a   Davis, Darren W ^a   McConkey, David J ^a   Symmans, W Fraser ^a   Valero, Vicente ^a   Jhingran, Anuja ^a   Tucker, Susan L ^a   Pusztai, Lajos ^a   Cristofanilli, Massimo ^a   Esteva, Francisco J ^a   Hortobagyi, Gabriel N ^a   Sahin, Aysegul A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Docetaxel; Doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; BIOPSY; BREAST TUMOR; DRUG EFFECT; FEMALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; IN SITU NICK-END LABELING; MIDDLE AGED; NEOPLASM, RESIDUAL; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037608711     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200301000-00007     Document Type: Article

References (25)

1. Meyn RE, Stephens LC, Hunter NR et al. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410-414.
2. Meyn RE, Stephens LC, Hunter NR et al. Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int J Cancer 1995;60:725-729.
3. Meyn RE, Stephens LC, Hunter NR et al. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995;6:443-450.
4. Milross CG, Mason KA, Hunter NR et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1313.
5. Schimming R, Mason KA, Hunter N et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999;43:165-172.
6. Symmans WF, Volm MD, Shapiro RL et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000;6:4610-4617.
7. Chang J, Ormerod M, Powles TJ et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-2152.
8. Stal O, Stenmark AM, Wingren S et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995;34:767-770.
9. Pharaoh PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-1973.
10. Bottini A, Berruti A, Bersiga Aet al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-2758.
11. Charpin C, Garcia S, Bonnier P et al. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol 1998;16:2025-2031.
12. Bonetti A, Zaninelli M, Leone R et al. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998;4:2231-2236.
13. Jansen, RL, Joosten-Achjanie SR, Volovics A et al. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res 1998;18:4455-4462.
14. Gasparini G, Barbareschi M, Doglioni C et al. Expression of bc1-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-198.
15. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Bio 1992;119:493-501.
16. Fisher B, Bryant J,Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
17. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
18. Feldman, LD, Hortobagyi, GN, Buzdar AU et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-2581.
19. Milas L, Hunter NR, Kurdoglu B et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995;35:297-303.
20. Krajewski S, Blomqvist C, Franssila K et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates quantitato combination chemotherapy and shorter survival in women in metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-4478.
21. Turner BC, Krajewski S, Krajewska M et al. BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol 2001;19:992-1000.
22. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-989.
23. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
24. Boise LH, Gottschalk AR, Quintans J et al. Bcl-2 and bcl-2 related proteins in apoptosis regulation. Curr Topics Microbiol Immunol 1995;200:107-121.
25. Harima U, Harima K, Shikata N et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998;124:503-510.